Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,priceHint,regularMarketChangePercent,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,regularMarketDayRange,regularMarketPreviousClose,bid,ask,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,currency,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchange,shortName,exchangeDataDelayedBy,market,marketState,epsTrailingTwelveMonths,twoHundredDayAverageChangePercent,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,UQ1.DE,225264000.0,45924700,,,-41343000,,-41556000,12375000,-32202000,-44458000,-44458000,-119000,-1551000,,,,213000,454000,44912000,32656000,3115000,,-41556000,-41556000,2908000.0,1049850000.0,135163000.0,228690000.0,5000000.0,363853000.0,2780000.0,6886000.0,-826287000.0,3107000.0,518000.0,2347000.0,18922000.0,260813000.0,32102000.0,16206000.0,2347000.0,59175000.0,282330000.0,5445000.0,70467000.0,5749000.0,2510000,-3876000,34603000,62618000,3302000,29176000,15849000,-1620000,-41273000,1862000,-8023000,-1161000,632000,-3876000,250228000.0,en-US,US,EQUITY,False,Delayed Quote,0,2.6400013,0.11833265,22.31 - 32.78,-7.829998,-0.2388651,22.31,32.78,5.03,24.012,0.93800163,0.03906387,27.113522,-2.1635208,1145821312,2,0.0,4.9602385,15,Europe/Berlin,CEST,7200000,24.95 - 24.95,24.95,24.44,25.39,finmb_171029664,XETRA,uniQure N.V.,USD,29,EUR,False,False,24.95,1630510559,0.0,24.95,24.95,24.95,392,GER,"UNIQURE N.V.  EO -,05",0,de_market,REGULAR,-2.594,-0.079794906,1.27,,,32.78,22.31,24.01,27.11,29,,45.92M,,35.59M,6.60%,95.75%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Mar 31, 2021",0.00%,-357.65%,-21.75%,-52.91%,37.86M,0.85,336.50%,-84.89M,-124.64M,-138.58M,-2.59,,260.81M,5.74,105.41M,46.09,8.80,5.03,-143.15M,-72.37M,Value,1105 BP,Healthcare,332,6,7,"uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.",Amsterdam,31 20 240 6000,2,1609372800,1622505600,5,Netherlands,http://www.uniqure.com,86400,4,Paasheuvelweg 25a,Biotechnology
t-1,UQ1.DE,240002000.0,45924700,,,-17118000,,-699000,11208000,2402000,-8265000,-8265000,-541000,-938000,,,,-16419000,34086000,42351000,31684000,-8853000,,-699000,-699000,3361000.0,1016018000.0,96490000.0,243905000.0,2082000.0,340395000.0,2711000.0,3024000.0,-784731000.0,3136000.0,542000.0,9907000.0,19167000.0,244932000.0,27334000.0,16419000.0,9907000.0,58414000.0,258911000.0,6618000.0,35617000.0,3772000.0,3105000,-2695000,34603000,3756000,-431000,3756000,-34527000,1587000,-37175000,2294000,-5784000,-1161000,-35660000,-2796000,231577000.0,en-US,US,EQUITY,False,Delayed Quote,0,2.6400013,0.11833265,22.31 - 32.78,-7.829998,-0.2388651,22.31,32.78,5.03,24.012,0.93800163,0.03906387,27.113522,-2.1635208,1145821312,2,0.0,4.9602385,15,Europe/Berlin,CEST,7200000,24.95 - 24.95,24.95,24.44,25.39,finmb_171029664,XETRA,uniQure N.V.,USD,29,EUR,False,False,24.95,1630510559,0.0,24.95,24.95,24.95,392,GER,"UNIQURE N.V.  EO -,05",0,de_market,REGULAR,-2.594,-0.079794906,1.27,,,32.78,22.31,24.01,27.11,29,,45.92M,,35.59M,6.60%,95.75%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Mar 31, 2021",0.00%,-357.65%,-21.75%,-52.91%,37.86M,0.85,336.50%,-84.89M,-124.64M,-138.58M,-2.59,,260.81M,5.74,105.41M,46.09,8.80,5.03,-143.15M,-72.37M,Value,1105 BP,Healthcare,332,6,7,"uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.",Amsterdam,31 20 240 6000,2,1609372800,1622505600,5,Netherlands,http://www.uniqure.com,86400,4,Paasheuvelweg 25a,Biotechnology
t-2,UQ1.DE,223323000.0,45924700,,,-53775000,,-53775000,10789000,-34513000,-44490000,-44490000,-812000,-942000,,,,0,1789000,46279000,36302000,-9285000,,-53775000,-53775000,4052000.0,1006898000.0,122614000.0,227893000.0,7666000.0,350507000.0,2694000.0,3496000.0,-784032000.0,23437000.0,518000.0,2333000.0,2714000.0,279493000.0,33350000.0,,2333000.0,55843000.0,287380000.0,223000.0,35494000.0,2348000.0,-3225000,-2183000,34603000,139000,4962000,139000,-34741000,2012000,-34709000,4849000,-2233000,-1161000,14713000,-2083000,254030000.0,en-US,US,EQUITY,False,Delayed Quote,0,2.6400013,0.11833265,22.31 - 32.78,-7.829998,-0.2388651,22.31,32.78,5.03,24.012,0.93800163,0.03906387,27.113522,-2.1635208,1145821312,2,0.0,4.9602385,15,Europe/Berlin,CEST,7200000,24.95 - 24.95,24.95,24.44,25.39,finmb_171029664,XETRA,uniQure N.V.,USD,29,EUR,False,False,24.95,1630510559,0.0,24.95,24.95,24.95,392,GER,"UNIQURE N.V.  EO -,05",0,de_market,REGULAR,-2.594,-0.079794906,1.27,,,32.78,22.31,24.01,27.11,29,,45.92M,,35.59M,6.60%,95.75%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Mar 31, 2021",0.00%,-357.65%,-21.75%,-52.91%,37.86M,0.85,336.50%,-84.89M,-124.64M,-138.58M,-2.59,,260.81M,5.74,105.41M,46.09,8.80,5.03,-143.15M,-72.37M,Value,1105 BP,Healthcare,332,6,7,"uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.",Amsterdam,31 20 240 6000,2,1609372800,1622505600,5,Netherlands,http://www.uniqure.com,86400,4,Paasheuvelweg 25a,Biotechnology
t-3,UQ1.DE,257922000.0,45924700,,,-42551000,,-42551000,11511000,-26866000,-38208000,-38208000,-169000,-970000,,,,0,1535000,39743000,28401000,-4343000,,-42551000,-42551000,7087000.0,1000389000.0,119836000.0,265505000.0,6153000.0,385341000.0,2692000.0,1066000.0,-730257000.0,24344000.0,496000.0,-7319000.0,2683000.0,314265000.0,29840000.0,,-7319000.0,55440000.0,319635000.0,222000.0,35373000.0,4942000.0,-2305000,-1716000,34603000,2539000,1313000,2539000,-28002000,1166000,-29991000,1772000,2332000,-1161000,9448000,-1715000,289795000.0,en-US,US,EQUITY,False,Delayed Quote,0,2.6400013,0.11833265,22.31 - 32.78,-7.829998,-0.2388651,22.31,32.78,5.03,24.012,0.93800163,0.03906387,27.113522,-2.1635208,1145821312,2,0.0,4.9602385,15,Europe/Berlin,CEST,7200000,24.95 - 24.95,24.95,24.44,25.39,finmb_171029664,XETRA,uniQure N.V.,USD,29,EUR,False,False,24.95,1630510559,0.0,24.95,24.95,24.95,392,GER,"UNIQURE N.V.  EO -,05",0,de_market,REGULAR,-2.594,-0.079794906,1.27,,,32.78,22.31,24.01,27.11,29,,45.92M,,35.59M,6.60%,95.75%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Mar 31, 2021",0.00%,-357.65%,-21.75%,-52.91%,37.86M,0.85,336.50%,-84.89M,-124.64M,-138.58M,-2.59,,260.81M,5.74,105.41M,46.09,8.80,5.03,-143.15M,-72.37M,Value,1105 BP,Healthcare,332,6,7,"uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.",Amsterdam,31 20 240 6000,2,1609372800,1622505600,5,Netherlands,http://www.uniqure.com,86400,4,Paasheuvelweg 25a,Biotechnology
